Letters to Editor
Sir, Breast cancer impact affects physical, social, psychological, and many other aspects of life among the cancer survivors. For the past two decades, there has been increasing number of studies highlighting the importance of physical activity and prevention, reduction, and reoccurrence of cancer. There is a paucity of information available on the functional capacity and quality of life (QoL) among the breast cancer survivors (BCS). The objective of this study is to determine the postchemotherapy changes on functional capacity and QoL among BCS. The functional capacity was determined by 6-min walk test (6MWT). [1] QoL was measured by the European Organization for Research and Treatment of Cancer (EORTC) breast cancer-specific QoL questionnaire (QLQ-BR23) (EORTC QLQ-BR23).
[2] The EORTC QLQ-BR23 questionnaire consists of 23 items under two sections, function and symptom. The answers for each question are in a Likert scale format. This questionnaire contains two scales, namely, the functional scale and the symptom scale. In addition to the above, the fatigue level was monitored by Schwartz Cancer Fatigue Scale (SCFS). [3] The university research and ethics committee (ACS/2016/57) approved the study protocol. A total of 116 female BCS, aged between 38 and 56 years, were included for the quasi-experimental, one-group pretest-posttest study design. The study was done in accordance with ethical guidelines for biomedical research on human subjects, the Indian Council for Medical Research, 2006 , and also in accordance with the guidelines of Helsinki Declaration, revised 2013. [4] The detailed purpose, procedure, risks, and benefits of the study were explained to them after obtaining signed consent form before data collection and assured confidentiality of the collected data. Anthropometrics were measured according to the recommendations of the International Standards for Anthropometric Assessment.
The total sample was stratified according to the Union for International Cancer Control/American Joint Committee on Cancer/International Association for the Study of Lung Cancer tumor, node, and metastasis staging. [5] Before the commencement and end of 4 th -week chemotherapy, 6MWT was measured according to the guidelines of American Thoracic Society, [6] QoL by EORTC QLQ-BR23, and fatigue level by SCFS.
Normality of collected data was established by Kolmogorov-Smirnov test. As the collected data follow normal distribution, descriptive statistics were expressed in mean ± standard deviation. Parametric tests (paired t-test) were used to analyze the significant difference between sessions. Among 116 females (46.7 ± 8.3 years old; 154.8 ± 6.6 cm; 82.2 ± 8.0 kg; 28.2 ± 3.6 kg/m 2 ), 47.5% were in Stage III and 52.5% were in Stage IV. There were 12 dropouts out of 116 BCS. However, they were analyzed using intention-to-treat analysis. Baseline and 4-week changes in 6MWT, EORTC QLQ-BR23, and SCFS were elaborated in Table 1 .
The change score of 6MWT, EORTC QLQ-BR23, and SCFS is 51.1 ± 13.4 m, 10.9 ± 1.8, and 8.8 ± 2.2, respectively. Minimal clinically important difference for 6MWT in patient with cancer is 43.1 m [1] and EORTC QLQ-BR23 is a 10-point change in score. [7] The minimal detectable change of SCFS is 5.7. [8] There is a clinically significant reduction in functional capacity and QoL with increased fatigue level among BCS. Thus, we can rightly say that the chemotherapy has a potential to reduce functional capacity and QoL and increases the fatigue level among BCS in 4 weeks.
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Beware! Reduced Functional Capacity and Quality of Life with Increased Fatigue Level among the Breast Cancer Survivors
Undergoing Chemotherapy in India Sir, Ziconotide is an N-type calcium channel antagonist which is used to treat chronic pain. It is a synthetic ω-conotoxin MVIIA, a hydrophilic conopeptide toxin which was originally isolated from Conus magus, a species of piscivorous cone snail [ Figure 1] . [1] At present, ziconotide is the only intrathecal (IT), United States Food and Drug Administration-approved, nonopioid analgesic. Preservative-free morphine is the other drug which is approved for IT use in chronic pain due to cancer and noncancer etiology. IT hydromorphone, clonidine, and baclofen are other drugs used off-label by clinicians. IT baclofen relieves pain due to spasticity in chronic pain conditions. When administered systemically, ziconotide has limited penetration across blood-brain barrier at the cost of unbearable side effects. Therefore, it is administered intrathecally to patients for better penetration across blood-brain barrier, better analgesia, and lesser side effects. Ziconotide blocks N-type calcium channels in the central nervous system, thereby effectively inhibiting neurotransmitter release (norepinephrine) that is responsible for pain at multiple synapses in the nervous system. It also Ziconotide: Indications, Adverse Effects, and Limitations in Managing Refractory Chronic Pain antagonizes N-type calcium channels at the cerebral cortex and the neurohypophysis. [2] IT ziconotide is initially started at a rate of 0.1 µg/h, i.e., 2.4 µg/day as a continuous infusion and is carefully monitored and titrated. The maximum recommended dose is 0.8 µg/h, i.e., 19.2 ug/day. Clinical trials in patients with refractory neuropathic and nociceptive pain have established the feasibility and usefulness of single dose or continuous infusion of IT ziconotide. [3] A continuous IT infusion is managed using an intrathecal drug delivery system (IDSS) infusion or as a patient-controlled analgesia system by the patient. The route of administration of this drug is the hurdle in its regular use. The drug needs to be delivered through an infusion pump (IDSS) and the dose needs to be carefully titrated. Second, adverse events are frequently noted with its use which interrupts the ongoing treatment. The commonly encountered adverse effects are cognitive and neuropsychiatric (confusion, memory impairment, and hallucinations), presyncopal and syncopal episodes, gait disturbances, meningitis, depression, and elevated creatine kinase. Hayek et al. presented their data of 15 patients who were enrolled in ziconotide trial and were followed up for
